findmyKOL

Michael Wechsler, MD

Enriched profile

Director, Cohen Family Asthma Institute; Edelstein Family Chair in Adult Pulmonary Medicine; Professor, Department of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine · National Jewish Health

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Denver, CO · West · United StatesSpecialtyPulmonary DiseaseFocusAsthma
Active KOLfindmyKOL type: NationalLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2013–2026

Michael Wechsler is Director, Cohen Family Asthma Institute; Edelstein Family Chair in Adult Pulmonary Medicine; Professor, Department of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine at National Jewish Health. OpenAlex indexes 448 publications with 23,998 citations (h-index 76); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Pulmonary Disease profiles in the findmyKOL directory.

Data verified 15 Oct 2026

Overview

Updated 14 Oct 2026

Michael Wechsler, MD, is Director, Cohen Family Asthma Institute at National Jewish Health. The public record shows 448 publications with 23,998 citations (h-index 76), centered on Asthma. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 26 companies, 5 NIH-funded awards (2013–2026).

  • Most recent indexed publication: 2026 · Allergy
  • Top research focus: Asthma
  • 7 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 26 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Asthma5 trialsVasculitis1 trialGranuloma1 trial

Research focus

OpenAlex concept fingerprint
Asthma

Drugs & molecules

across trials, industry payments and publications
Nucalageneric · MepolizumabClinical trials—Industry payments131Publications2Dupixentgeneric · DupilumabClinical trials—Industry payments167Publications—Fasenrageneric · BenralizumabClinical trials—Industry payments160Publications—Tezspiregeneric · TezepelumabClinical trials—Industry payments125Publications—Airsuprageneric · Albuterol / budesonideClinical trials—Industry payments40Publications—Xolairgeneric · OmalizumabClinical trials—Industry payments14Publications—Joenjageneric · LeniolisibClinical trials—Industry payments12Publications—Breztrigeneric · Budesonide / formoterol / glycopyrroniumClinical trials—Industry payments8Publications—Olodaterol / tiotropiumClinical trials—Industry payments2Publications—Stiolto RespimatClinical trials—Industry payments2Publications—Wayrilzgeneric · RilzabrutinibClinical trials—Industry payments2Publications—Arexvygeneric · Respiratory syncytial virus pre-fusion F proteinClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
AstraZeneca Pharmaceuticals LPClinical trials—Industry payments390GlaxoSmithKline, LLC.Clinical trials—Industry payments319Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments264Genzyme CorporationClinical trials—Industry payments252AstraZeneca ABClinical trials—Industry payments35AstraZeneca UK LimitedClinical trials—Industry payments29Amgen Inc.Clinical trials—Industry payments23Sanofi-Aventis U.S. LLCClinical trials—Industry payments23Merck Sharp & Dohme LLCClinical trials—Industry payments16Genentech USA, Inc.Clinical trials—Industry payments14Pharming Healthcare, Inc.Clinical trials—Industry payments12Acerta Pharma LLCClinical trials—Industry payments7Pfizer Inc.Clinical trials—Industry payments5Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments3Sanofi Us Services Inc.Clinical trials—Industry payments3Brigham and Women's HospitalClinical trials2Industry payments—National Jewish HealthClinical trials2Industry payments—Abbvie Inc.Clinical trials—Industry payments1Aero US IncClinical trials—Industry payments1Areteia TherapeuticsClinical trials1Industry payments—AstraZenecaClinical trials1Industry payments—Circassia Inc.Clinical trials—Industry payments1Eli Lilly and CompanyClinical trials—Industry payments1F. Hoffmann-La Roche AGClinical trials—Industry payments1Gilead Sciences, Inc.Clinical trials—Industry payments1Halozyme IncClinical trials—Industry payments1Incyte CorporationClinical trials—Industry payments1kaleo, Inc.Clinical trials—Industry payments1Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments1Spiro Medical, Inc.Clinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
448publications

Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.

23,998citations

Total citations across indexed works.

76h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials ↓
26companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
5NIH grants · 2013–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 14 Oct 2026

26 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    73.3%
    Corticosteroid44.8%
    Breo Ellipta44%Arnuity Ellipta20%Trelegy Ellipta18%Symbicort17%
    Part D<11 patients
    Interleukin-5 Antagonist13.8%
    Nucala100%
    Part D<11 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    17.2%
    Corticosteroid17.2%
    Prednisone100%
    Part D≥13 patients
  • Dermatology

    9.5%
    Interleukin-4 Receptor alpha Antagonist9.5%
    Dupixent Syringe100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 14 Oct 2026

5 NIH research awards on record, funded 2013–2026 per NIH RePORTER. The latest:

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • ResearchGate

    researchgate.net/profile/Michael-Wechsler-4

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗

Mentions by others

where others cite or feature them
  • Facebook

    m.facebook.com/CheckRare/posts/michael-wechsler-md-director-asthma-program-national-jewish-health-and-univ-of-c/758267681367294

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →m.facebook.com ↗
  • X / Twitter

    x.com/NJHealth/status/1788599817385521620

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Diplomate

    ABIM Subspecialty of Critical Care Medicine

    2018
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nationaljewish.org ↗
  • Diplomate

    American Board of Internal Medicine

    2009
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nationaljewish.org ↗
  • Diplomate

    ABIM Subspecialty of Pulmonary Disease

    2009
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nationaljewish.org ↗
  • MMSc

    Harvard Medical School

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nationaljewish.org ↗
  • MD

    McGill University School of Medicine

    1993
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nationaljewish.org ↗

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Professor

    Medicine-Pulmonary Sciences & Critical Care, University of Colorado School of Medicine (Anschutz Medical Campus)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗

Media & interviews

press, podcasts and appearances
  • Featured lecturer

    Pulmcast: 'Management of Severe Asthma in 2024 and Beyond'

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmcast.com ↗
  • Host

    Medscape 'InDiscussion: Moderate to Severe Asthma' podcast/video series

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medscape.com ↗
  • Video interview

    HCPLive: 'Asthma Patients During COVID-19'

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.